Anthropic blocks Claude from cloning existing video games

Anthropic has warned that artificial intelligence is approaching Recursive Self-Improvement (RSI) capability, a threshold at which AI systems become capable of training and improving themselves. RSI represents a potential inflection point where AI capabilities could accelerate dramatically without human intervention. The company's warning signals growing concern within the AI industry about the trajectory of AI development and the implications of systems that can autonomously enhance their own performance.

Anthropic reported $17 billion in Q3 revenue, up 47% from Q2, but swung back to an operating loss of $23.3 billion for the quarter. The revenue growth rate signals deceleration ahead of the company's planned IPO this month. The loss reflects continued heavy investment in AI infrastructure and model development despite strong top-line growth.

Anthropic has launched tools that provide transparency into how enterprise customers spend money on its AI models, ahead of the company's planned IPO. The tools allow users to track and understand their AI expenditures and usage patterns. This move signals Anthropic's effort to demonstrate business value and operational transparency to investors and customers before going public.

Anthropic acquired Mithril Medicine, a single-person startup developing treatments for rare forms of muscular dystrophy, signaling the AI developer's expanding focus on drug discovery. The acquisition follows Anthropic's stated work with Bristol Myers Squibb, BigHat Biosciences, and four other partners in biotech. The move reflects growing interest among AI companies in applying large language models and AI capabilities to pharmaceutical research and development.